Table 2.

Comparison of patients with SSc and patients with SSc–sarcoidosis overlap syndrome.

Total, N = 1977SSc, n = 1971SSc–Sarcoidosis, n = 6RR (95% CI)
Demographics
        Age, yrs, median (range)48.3 (1.5-85.0)48.3 (1.5-89.0)43.8 (34.3-54.5)NA
        Sex
                Male359 (18.15)358 (18.16)1 (16.66)
                Female1618 (81.84)1613 (81.83)5 (83.33)1.11 (0.13-9.47)
SSc manifestations
        Diffuse subtype637 (32.22)636 (32.26)1 (16.66)0.48 (0.05-4.28)
        Calcinosis cutis460 (23.26)459 (23.28)1 (16.66)0.64 (0.07-5.44)
        Raynaud manifestation1872 (94.68)1866 (94.67)6 (100)NA
        Esophageal hypomobility1643 (83.1)1638 (83.1)5 (83.33)0.98 (0.11-8.33)
        Sclerodactyly1674 (84.67)1669 (84.67)5 (83.33)0.87 (0.10-7.41)
        Telangiectasia1304 (65.95)1300 (65.95)4 (66.66)0.95 (0.17-5.17)
        ILD694 (35.1)690 (35)4 (66.66)6.65 (0.74-59.40)
        Pulmonary HTN494 (24.98)491 (24.91)3 (50)7.12 (0.74-68.30)
        Scleroderma renal crisis131 (6.63)131 (6.65)0 (0)NA
        Abnormal nailfold capillaries685 (34.64)684 (34.7)1 (16.66)0.48 (0.04-5.33)
        Digital ulcers658 (33.28)657 (33.33)1 (16.66)0.39 (0.05-3.34)
        ACA438 (22.15)438 (22.22)0 (0)NA
Comorbidities
        CAD166 (8.40)166 (8.42)0 (0)NA
        Systemic HTN448 (22.66)447 (22.67)1 (16.66)0.68 (0.08-5.82)
        DM129 (6.53)129 (6.54)1 (16.66)2.84 (0.33-24.10)
        Hyperlipidemia179 (9.05)178 (9.03)1 (16.66)2.01 (0.24-17.10)
        Peripheral vascular disease60 (3.03)60 (3.04)0 (0)NA
        Cancer227 (11.48)227 (11.51)0 (0)NA
        Stroke45 (2.28)44 (2.23)1 (16.66)8.59 (1.02-72.00)
        Atrial fibrillation100 (5.06)100 (5.07)0 (0)NA
  • All values are n (%) unless otherwise indicated. Bold denotes statistical significance. ACA: anticentromere antibody; CAD: coronary artery disease; DM: diabetes mellitus; HTN: hypertension; ILD: interstitial lung disease; NA: not applicable; RR: relative risk; SSc: systemic sclerosis.